Novavax Inc. (NVV1)

Overview

Novavax, Inc. is at the forefront of advancing public health through biotechnological innovation, focusing primarily on the development and commercialization of vaccines to counteract serious infectious diseases. Emphasizing an improved health agenda, the company leverages a unique vaccine platform that marries recombinant protein technology, cutting-edge nanoparticle science, and its proprietary Matrix-M adjuvant to amplify the body's immune response to pathogens. Targeting some of the most pressing health challenges of our time, including the ongoing battle against COVID-19 and influenza, Novavax is dedicated to providing effective vaccine solutions worldwide. Founded in 1987, it is headquartered in Gaithersburg, Maryland, marking over three decades of contributions to the field of biotechnology and public health.

Products and Services

Nuvaxovid/ Covovax/ Novavax COVID-19 Vaccine, Adjuvanted: This represents Novavax's premier commercialized product, the NVX-CoV2373 vaccine, which is available under various brand names such as Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted. Designed for the adult and adolescent populations, it serves as a primary series vaccine and is also applicable for homologous and heterologous booster shots. Building on the company's innovative approach, this vaccine aims to provide a robust defense against COVID-19, highlighting Novavax's commitment to combating the pandemic.

R21/Matrix-M Adjuvant Malaria Vaccine: Beyond its noteworthy contributions to the COVID-19 crisis, Novavax is also venturing into malaria, one of the most enduring public health challenges globally. The company is developing the R21/Matrix-M adjuvant malaria vaccine, a promising candidate that demonstrates Novavax's application of its technology and expertise beyond the realm of viral infections. This venture underscores the company's broader commitment to addressing urgent health challenges through innovative vaccine development.